RedHill Biopharma (RDHL) Debt to Equity (2022)
RedHill Biopharma (RDHL) has disclosed Debt to Equity for 1 consecutive years, with -$2.38 as the latest value for Q4 2022.
- Quarterly Debt to Equity changed N/A to -$2.38 in Q4 2022 from the year-ago period, while the trailing twelve-month figure was -$2.38 through Dec 2022, changed N/A year-over-year, with the annual reading at -$2.38 for FY2022, N/A changed from the prior year.
- Debt to Equity for Q4 2022 was -$2.38 at RedHill Biopharma.
- The five-year high for Debt to Equity was -$2.38 in Q4 2022, with the low at -$2.38 in Q4 2022.